Temozolomide

Catalog No.S1237 Synonyms: CCRG81045, NSC 362856

Temozolomide Chemical Structure

Molecular Weight(MW): 194.15

Temozolomide is a monofunctional SN-1 alkylating agent that can modify nitrogen atoms in the DNA ring and the extracyclic oxygen group, chemically converted to MTIC and degrades to methyldiazonium cation, which transfers methyl groups to DNA at physiologic pH. A DNA damage inducer in L-1210 and L-1210/BCNU cells.

Size Price Stock Quantity  
In DMSO USD 64 In stock
USD 70 In stock
USD 170 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

6 Customer Reviews

  • C57BL/6 mice were implanted in the striatum with citrine-GL26-Cherry-HMGB1, which were stably transfected to express the YFP citrine and HMGB1 fused to red fluorescent protein cherry. Fourteen days later, they were treated with saline, Ad-TK+Ad-Flt3L, or Ad-TK+Ad-Flt3L+TMZ (temozolomide). Five days after treatment, the cellular location of cherry-HMGB1 in these cells was assessed by confocal microscopy. Arrows, tumor cells (green) with cytoplasmic HMGB1 (red).

    Clin Cancer Res 2014 20(6), 1555-65. Temozolomide purchased from Selleck.

    Talazoparib and temozolomide exhibit marked combinatorial efficacy in PDXs. A, Western blot against MGMT by near-infrared imaging in PDX models.

    Clin Cancer Res, 2017, 23(2):523-535. Temozolomide purchased from Selleck.

  • J Control Release, 2018, 269:245-257. Temozolomide purchased from Selleck.

    Viability of U87 cells(A) assessed by the Alamar blue assay, 72 h after transfection with siRNA anti-survivin (siSURV) or with siMUT and/or cell incubation with the chemotherapeutical drugs temozolomide (TMZ) and Bliss interaction index (B) determined for the combined effects on cell viability of survivin silencing plus treatment with each drug. Cells were transfected, for 4 h, with (14Ser)2N5/siRNA/HL complexes and, after an additional period of 20 h, cells were incubated with 400 μM TMZ(A) for 48 h. Results, representative of at least three independent experiments, are expressed as a percentage of the nontreated control cells. Combined treatment (dotted bar) was compared with the single drug treatment (gray bar) (**p < 0.01, ***p < 0.001) and the Bliss interaction index of each combined treatment was compared with the theoretical value expected for an additive effect (1.0) (#p < 0.05, ns, non-significant).

    Eur J Pharm Biopharm, 2016, 104:7-18.. Temozolomide purchased from Selleck.

  • Cells were plated and 12 h after plating were treated with MMF (5 µM), FTY720 (50 nM), Temozolomide (TMZ, 3 µM) or in combination as indicated for 12 h. Cell viability was assessed by live / dead assay.

    Cancer Biol Ther, 2014, 15(12):1646-57. Temozolomide purchased from Selleck.

    Establishment of TMZ-resistant (TR) GBM cell lines. a-d, Evaluation of temozolomide resistance in four glioblastoma cell lines. Cells were cultured in the presence of 5-600 μM of TMZ. A dose-dependent association between the survival rate of cells and TMZ concentration can be observed. Each group was cultured for 24 h in the presence of different concentrations of TMZ, followed by an evaluation of IC50 for TMZ inhibited growth in A172-TR/A172, U118-TR/U118, U251-TR/U251 and U87-TR/U87

    Neurochem Res, 2016, 41(12):3192-3205. Temozolomide purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Temozolomide is a monofunctional SN-1 alkylating agent that can modify nitrogen atoms in the DNA ring and the extracyclic oxygen group, chemically converted to MTIC and degrades to methyldiazonium cation, which transfers methyl groups to DNA at physiologic pH. A DNA damage inducer in L-1210 and L-1210/BCNU cells.
Features Methazolastone is a second-generation alkylating agent.
Targets
DNA replication [1]
(L-1210, L-1210/BCNU cells)
In vitro

Methazolastone causes formation of DNA alkali-labile sites which are present in similar amounts and repaired at a similar rate in L-1210 and L-1210/BCNU cell lines. In L-1210 but not in L-1210/BCNU methazolastone induces an arrest of cells in SL-G2-M phases.[1] Methazolastone sensitivity of both chemo-sensitive and resistant cells (D54-R and U87-R) is enhanced significantly under hyperoxia. Both Methazolastone and hyperoxia are associated with increased phosphorylation of ERK p44/42 MAPK (Erk1/2), but to a lesser extent in D54-R cells, suggesting that Erk1/2 activity may be involved in regulation of hyperoxia and Methazolastone-mediated cell death. Hyperoxia enhances Methazolastone toxicity in GBM cells by induction of apoptosis, possibly via MAPK-related pathways. [2] Methazolastone induces in monocytes the DNA damage response pathways ATM-Chk2 and ATR-Chk1 resulting in p53 activation. [3] Chronic Methazolastone exposure results in acquired Methazolastone-resistance and elevates miR-21 expression. [4] Methazolastone treatment triggers endoplasmic reticula (ER) stress with increased expression of GADD153 and GRP78 proteins, and deceases pro-caspase 12 protein. Methazolastone induces autophagy through mitochondrial damage- and ER stress-dependent mechanisms to protect glioma cells. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly NETtOGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVmwRoNYPDhiaB?= NVv6eWg6UUN3ME2xN|kvOjEkgJpCtgKBkTVwOUWg{txO NGr3[2czPTl4MEK4Ni=>
KellyCis83 MmnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3oPJU1QCCq Moi5TWM2OD1{NUGuNFDjiIoEsfMAjVE2Njd3IN88US=> NHfifnkzPTl4MEK4Ni=>
SK-N-AS Mo\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjkNo41QCCq NG\peFVKSzVyPUKyO{44OOLCidMx5qCKOjJwMUWg{txO NUX2OpRLOjV7NkCyPFI>
SK-N-ASCis24 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYi0PEBp NYLWNGN3UUN3ME20PFAvPjEkgJpCtgKBkTFyMT6xOUDPxE1? NHG1S2YzPTl4MEK4Ni=>
CHP-212 M4S2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV60PEBp NHv5b2FKSzVyPUeuPVfjiIoEsfMAjVAvPjlizszN M{fWO|I2QTZyMkiy
CHP-212Cis100 M{OxNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DQSlQ5KGh? M2e1bmlEPTB;OT61OgKBkcLz4pEJNE45QCEQvF2= MWqyOVk3ODJ6Mh?=
U87  MmC2SpVv[3Srb36gRZN{[Xl? M2LNPFExOCEQvF2= Mn7kNlQuPzJiaB?= MXjpcoR2[2W|IFTjVlEh\XiycnXzd4lwdg>? M1fwVVI2QDB6OE[4
LN229 NYHifHp7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvSVYZHOC13MDFOwG0> MXLJR|UxRTF4IN88US=> NVzxb5B7OjV5NUCyO|M>
TR-LN229 NFjrfo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXWwMVUxKM7:TR?= MljzTWM2OD15NzFOwG0> MYmyOVc2ODJ5Mx?=
U87  MmL0RZBweHSxc3nzJGF{e2G7 NVHCTZQ3OOLCk{KwNQKBkcL3TR?= MVuyOEBp M37odoVvcGGwY3XzJGNSKGmwZIXj[YQh[XCxcITvd4l{ M3PGfVI2PjhzNk[4
U251MG NGrNbHRCeG:ydH;zbZMhSXO|YYm= MXyxNFDDqM7:TR?= NYLNVph{PDhiaB?= NFLhdmVRSlN? NYLER|g3cW6mdXPld{BieG:ydH;zbZM> Ml\CNlU3QDB2NkS=
U87MG MlXWRZBweHSxc3nzJGF{e2G7 M3G1WFExOMLizszN Mkn3OFghcA>? MUHQRnM> MYDpcoR2[2W|IHHwc5B1d3Orcx?= Mkn4NlU3QDB2NkS=
U87 MnLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnqPGI2OC1|NUCg{txO NV\iPIlUPDkEoHlCpC=> MmH0bY5pcWKrdIOgZ4VtdCCpcn;3eIghe2yrZ3j0cJk> NXf5d4R6OjV3NUSyNlM>
U118  M4jvUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVy1NE0{PTBizszN NYTxPXlWPDkEoHlCpC=> MU\pcohq[mm2czDj[YxtKGe{b4f0bEB{dGmpaITsfS=> NW\zV3hjOjV3NUSyNlM>
U87 MkXHSpVv[3Srb36gRZN{[Xl? MXeyOVAwOzVyIN88US=> MlTTOFjDqGkEoB?= M3;weYVvcGGwY3XzJHROYC2rbnT1Z4VlKHBvUFvDMZBidiCmZXPy[YF{\Q>? NH;ielQzPTV3NEKyNy=>
U118  NWXUVVlCTnWwY4Tpc44hSXO|YYm= MWiyOVAwOzVyIN88US=> NHvLeVU1QMLiaNMg MoTy[Y5p[W6lZYOgWG1ZNWmwZIXj[YQheC2SS1OtdIFvKGSnY4LlZZNm MXmyOVU2PDJ{Mx?=
U87 M{jCRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXv[5dHOjVyL{O1NEDPxE1? MYe0POKhcMLi NVXm[nZNcW6lcnXhd4V{KHSqZTDw[ZJk\W62YXflJI9nKGOnbHzzJIlvKFNiYX7kJGczN04EoHPveJJm[XSnZDD3bZRpKFSPWB?= MXSyOVU2PDJ{Mx?=
A375 NIT2ZnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fFdlQ5yqCqwrC= NIHjfFFKSzVyPUK2OUDPxE1? M2O0fFI2PTJ2NUWy
A2058 MlnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17PZVQ5yqCqwrC= Mn7kTWM2OD1zMjFOwG0> M1jITFI2PTJ2NUWy
M238 NEj6Z|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfob|E1QMLiaNMg M4nXWGlEPTB;NECg{txO NFrNZWQzPTV{NEW1Ni=>
M249 NYjHdHVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjNN41xPDkEoHlCpC=> M4jEeWlEPTB;MkW0JO69VQ>? NHTlUYozPTV{NEW1Ni=>
M21 NWjMXINtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33WPFQ5yqCqwrC= NGCxdlVKSzVyPUKyNUDPxE1? M3Hzb|I2PTJ2NUWy
U251 NVS2e2h4S3m2b4TvfIl1gSCDc4PhfS=> M3;pcFIxKM7:TdMg M3zrSVQ5yqCqwrC= NWjwZVlsemWmdXPl[JMhfGinIIDldoNmdnSjZ3XzJI9nKGOxbH;ubYV{KG[xcn3l[C=> MmfZNlU1OzR|OEG=
LN229 M{e4cWN6fG:2b4jpeJkhSXO|YYm= MlmxNlAh|ryPwrC= M2LkUFQ5yqCqwrC= MYPy[YR2[2WmczD0bIUheGW{Y3XueIFo\XNib3[gZ49td26rZYOg[o9zdWWm MVSyOVQ{PDN6MR?=
U373MG-LUC MkGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInudpQ4OiCq Mn;ITWM2OD54MECg{txO NED4WokzPTR|MUm1Ny=>
U87  NGfvW2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrLNFBxOjVvMkCwJO69VQ>? MkTGOFjDqGkEoB?= NYLnem5vcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M4jKe|I2PDByN{S1
U251 M{LzN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTUUmIzPS1{MECg{txO MXS0POKhcMLi MYLpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M3H2NFI2PDByN{S1
U251 NUKwcI1QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnLcpFvOTByLUSwNEDPxE1? NXzTVGFKPzJxOU[gbC=> MUf0bIUh[W62aT3wdo9tcW[ncnH0bZZmKGWoZnXjeEBk[W5iYnWg[Y5p[W6lZXSgZpkh\2:|c4nwc4wh\W6qYX7j[YQhyqB? NUDYdY5JOjV|N{WyO|E>
U373 NYXvXId6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nafFExOC12MECg{txO NWrwUXJ5PzJxOU[gbC=> MlXseIhmKGGwdHmtdJJwdGmoZYLheIl3\SCnZn\lZ5Qh[2GwIHLlJIVvcGGwY3XkJIJ6KGexc4P5dI9tKGWwaHHuZ4VlKMLi MUGyOVM4PTJ5MR?=
U343 M{nEfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XYUlExOC12MECg{txO Mn;wO|IwQTZiaB?= MlLYeIhmKGGwdHmtdJJwdGmoZYLheIl3\SCnZn\lZ5Qh[2GwIHLlJIVvcGGwY3XkJIJ6KGexc4P5dI9tKGWwaHHuZ4VlKMLi NHvM[HEzPTN5NUK3NS=>
U87MG-luc2 M3zZSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPsdpcyODBvNECwJO69VQ>? M4Hzd|czNzl4IHi= M4OzVJRp\SCjboTpMZBzd2yrZnXyZZRqfmViZX\m[YN1KGOjbjDi[UBmdmijbnPl[EBjgSCpb4PzfZBwdCCnbnjhcoNm\CEEoB?= NWK2SHFwOjV|N{WyO|E>
U87 NHHUVFdHfW6ldHnvckBCe3OjeR?= MofJNlAxKM7:TR?= Mm\6OFghcA>? NXXXbo1lcW6lcnXhd4V{KEKUQ1OzJI1TVkFiZYjwdoV{e2mxbh?= NYqydIdFOjV|M{e3NlE>
U251 NV21O|ZNTnWwY4Tpc44hSXO|YYm= Mn\tNlAxKM7:TR?= M2Lrd|Q5KGh? MXnpcoNz\WG|ZYOgRnJESzNibWLORUBmgHC{ZYPzbY9v NF3kTW0zPTN|N{eyNS=>
A172 M1jRfGZ2dmO2aX;uJGF{e2G7 NFjJflkzODBizszN NXfSelNxPDhiaB?= NIf3SWVqdmO{ZXHz[ZMhSlKFQ{OgcXJPSSCneIDy[ZN{cW:w M4HBSVI2OzN5N{Kx
U251 Mli5SpVv[3Srb36gRZN{[Xl? MmC0NlAxKM7:TR?= MWK0PEBp M1LZOIlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBDWkODMTygRnJESTJuIGLBSFUyKGGwZDDGRW5ETDJ? NEjPcmczPTN|N{eyNS=>
A172 MnfZSpVv[3Srb36gRZN{[Xl? MXSyNFAh|ryP MVq0PEBp NG\y[JhqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhSlKFQUGsJGJTS0F{LDDSRWQ2OSCjbnSgSmFPS0R{ NXXSdVE2OjV|M{e3NlE>
U87 MVTGeY5kfGmxbjDBd5NigQ>? MVyyNFAh|ryP NYnNPIlUOjRxN{KvNVIxKGh? MlfZbY5kemWjc3XzJO6{UDKDWDDmc4NqKG[xcn3heIlwdiC2aX3lMYRmeGWwZHXueIx6 NHvLWY0zPTN|N{eyNS=>
U251 MWHGeY5kfGmxbjDBd5NigQ>? MoL5NlAxKM7:TR?= MXKyOE84Oi9zMkCgbC=> M{\2Solv[3KnYYPld{DPu0h{QWig[o9kcSCob4LtZZRqd25idHnt[U1l\XCnbnTlcpRtgQ>? MoPoNlU{Ozd5MkG=
A172 NGLVRpVHfW6ldHnvckBCe3OjeR?= M4jEVVIxOCEQvF2= NVvlPFlEOjRxN{KvNVIxKGh? MYPpcoNz\WG|ZYOg{tNJOkG[IH\vZ4kh\m:{bXH0bY9vKHSrbXWt[IVx\W6mZX70cJk> NHT5VHUzPTN|N{eyNS=>
SNB19V M4T0eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4i2blch\A>? M4PudWROW09? NFfJc2xIUTVyPUO1MlfDuTF{IN88US=> NHjvUWEzPTJ5N{S0NS=>
SNB19M NGnXWpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HRPVch\A>? NITKRZpFVVOR M2e3bmdKPTB;NE[5MlnDuTh6IN88US=> MkDFNlUzPzd2NEG=
SNB19VR NWj1fJlUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnBV5Y4KGR? NXLaeVJWTE2VTx?= NIDZW5RIUTVyPUK4NE4zyrFzODFOwG0> MVWyOVI4PzR2MR?=
U373V NV24fI5MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPJUGc4KGR? NV\veYF2TE2VTx?= M{D5SmdKPTB;NkiuNOKyOzJizszN MWiyOVI4PzR2MR?=
U373M NWfvV3I6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLyO{Bl NYrXTJRvTE2VTx?= MXnHTVUxRTN4OD63xtE5PiEQvF2= NYC3dIlxOjV{N{e0OFE>
U373VR NVn2OZY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXZO{Bl NXjKfmduTE2VTx?= MkewS2k2OD1{OEiuPOKyOzNizszN Ml7kNlUzPzd2NEG=
U87MG M1O4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{j3VVch\A>? MXvEUXNQ NXOxXYNNT0l3ME2zPE4{yrF{MDFOwG0> M2nsXlI2Ojd5NESx
HCT116 M3nXcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\LSVhJPyCm MV7EUXNQ NFr2[GxIUTVyPUW3PU46yrF|MjFOwG0> M2m4clI2Ojd5NESx
DLD1 NH;se2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{n1Xlch\A>? NVXVdFluTE2VTx?= Mon0S2k2OD13MEGuOOKyQTNizszN NETx[mwzPTJ5N{S0NS=>
MRC5 MnfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrwUIY4KGR? MlWwSG1UVw>? NWDKT2lwT0l3ME20OFkvPMLzODFOwG0> M{DJ[FI2Ojd5NESx
SNB19V  MXvGeY5kfGmxbjDBd5NigQ>? M2jwblExOCEQvF5CpHROYg>? MVOwMVczKGh? Ml;JbY5kemWjc3XzJO6{UDKDWDDlfJBz\XO|aX;uJIJmfHenZX6gNVYh[W6mIEeyJIg> NV;uOJIzOjV{N{e0OFE>
T98G  NIK0eWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoCyOU8yOC9zNTFOwG0> NHT5bW8zPMLiaB?= NGnNNYlqdmS3Y3XzJINmdGxiZHXheIgh\G:|ZT3k[ZBmdmSnboTsfUBi\nSncjDjc45kd22rdHHueE11\W2xen;sc41q\GVid3n0bEBPWGV4LWDEWC=> NIPTcW0zPTJ4Mkm2NS=>
U251  Mo\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVu1M|ExNzF3IN88US=> NFjDT|EzPMLiaB?= NEnPWXpqdmS3Y3XzJINmdGxiZHXheIgh\G:|ZT3k[ZBmdmSnboTsfUBi\nSncjDjc45kd22rdHHueE11\W2xen;sc41q\GVid3n0bEBPWGV4LWDEWC=> M1HYS|I2OjZ{OU[x
T98G  NWm4VGZtTnWwY4Tpc44hSXO|YYm= NYTXZWpOOTVizszN M{PrXFI1yqCq MoXJbY5kemWjc3XzJGRPSS2ocnHncYVvfGG2aX;uJIlvKE6SZU[tVGRVKHS{ZXH0[YQh\2yrb33hJINmdGy| M2Do[FI2OjZ{OU[x
U251  M2n1UWZ2dmO2aX;uJGF{e2G7 NXm3clFiOTVizszN M2nnO|I1yqCq MoLabY5kemWjc3XzJGRPSS2ocnHncYVvfGG2aX;uJIlvKE6SZU[tVGRVKHS{ZXH0[YQh\2yrb33hJINmdGy| M121NlI2OjZ{OU[x
U-87 MG M4XB[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HHPVczKGh? MXXJR|UxRTBwOUOgcW3DqA>? MmjyNlUzPDV|M{K=
U-118 MG MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEC2c404OiCq M1zsW2lEPTB;MT6wOUBuVcLi M37YU|I2OjR3M{Oy
U87 M2H6XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTSNlQhcA>? NVLnUpJLUUN3ME2yOlAvOzRizszNxsA> MYeyOVE4OzJ|Mx?=
U87 GSLCs NUHJd3lrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzKTpczPCCq NUCwdWw5UUN3ME23OlYvOTFizszNxsA> M3nocFI2OTd|MkOz
U87MG M{ThfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVz4d29kPzJiaB?= MX\JR|UxRTF3Lk[yOUDPxE4EoB?= NIHWfm4zPTB3MEmxOS=>
U251 NUTTRWU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmf1NVAxNTRyMDFOwG0> NFniOpc1QCCq NFftPI1FVVOR MVPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M4jISlI1PjJ|N{O2
U87 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVOxNFAuPDByIN88US=> MkLlOFghcA>? MmL3SG1UVw>? Mln4bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NFXBRYEzPDZ{M{ezOi=>
MDA-MB-231-br Mo\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHv6OZoxNTFyIN88US=> M1\GSFQ5KGh? M3rQNWROW09? M2GwdIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NX;z[WJ{OjR4MkO3N|Y>
HCC-1937 NHXzSYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\3UHgxNTNyMDFOwG0> MUS0PEBp NH;NUWVFVVOR MX7pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M1rBPFI1PjJ|N{O2
MDA-MB-231 M2fZVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVWwMVQxKM7:TR?= M4\PV|Q5KGh? M4DJd2ROW09? MVnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NETKT4YzPDZ{M{ezOi=>
MDA-MB-468 NIjkW2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDQPXkxNTVyMDFOwG0> MYm0PEBp NVv6UlMxTE2VTx?= NV2xRllPcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Mn\YNlQ3OjN5M{[=
T47D MmPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfVZolEOC1zMECg{txO NWDJNmxbPDhiaB?= M1HFTWROW09? MmfTbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MnewNlQ3OjN5M{[=
MCF7 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{L0T|AuOTByMDFOwG0> M{WycVQ5KGh? NWHPRoN3TE2VTx?= NIC5[mRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M333R|I1PjJ|N{O2
Hs683 MoHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmflNE0yODByIN88US=> MWe5OkBp NUHD[XdxUUN3ME2xNlgvQSEQvF2= NWrl[3lvOjR2OUW5NFc>
U87 NV;3W21RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\Ub|AuOTByMDFOwG0> NXrYTlJjQTZiaB?= NEG2cpVKSzVyPUG4MlQ2KM7:TR?= M1jlXVI1PDl3OUC3
LNZ308 M1fneGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm[0NE0yODByIN88US=> MUC5OkBp NH7rUmFKSzVyPUOyOk44KM7:TR?= NWjCSVJNOjR2OUW5NFc>
U87 M1\QfWFxd3C2b4Ppd{BCe3OjeR?= MoPzNVAxKM7:TR?= NUT3[mdJPDhiaB?= MWjEUXNQ MmXEbY5kemWjc3XzJJRp\SClYYPwZZNmNTNxNzDhZ5Rqfmm2eR?= M2P4VVI1PDhzNUi2
U251  NFPybJBCeG:ydH;zbZMhSXO|YYm= MWSxNFAh|ryP NEGzV4Q1QCCq NITVXVBFVVOR NUnib3VicW6lcnXhd4V{KHSqZTDjZZNx[XOnLUOvO{Bi[3Srdnn0fS=> NHPN[IQzPDR6MUW4Oi=>
U251 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVGyOEBp NVHkWndoUUN3ME24Ok4zQeLCidMx5qCKOS53ODFOwG0> Mon2NlQ{OjZ7NUS=
U251 NIG4cplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LkT|Q5KGh? NUPEZ2F3UUN3ME23OU4{POLCidMx5qCKOS5yMjFOwG0> MkDONlQ{OjZ7NUS=
U251 M2PoT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LpOlczKGh? MljwTWM2OD15Mj60NwKBkcLz4pEJNU41PSEQvF2= NEizPWEzPDN{Nkm1OC=>
U251 M{Ox[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXyO5Y6QTZiaB?= M{XPWWlEPTB;NkmuPFLjiIoEsfMAjVMvODRizszN NXTZNJhIOjR|Mk[5OVQ>
T98G NHTuRmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXWwMVc2OCEQvF2= M1zGOVczNzl4IHi= MWrpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NUnBe4hjOjR|MkSwPFA>
U251-MG M4faXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIm3XWQxNThyMDFOwG0> NYizb2lUPzJiaB?= MlvabY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NVG2OotROjRyOUO2N|A>
D54-MG NV7sNnljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1L2WVAuQDByIN88US=> Mln6O|IhcA>? NXz3XlFOcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NUPEbWgzOjRyOUO2N|A>
SHG-44 M{XmPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnf6NVAuOjByIN88US=> MmnZPVYhcA>? MWTJR|UxRTlwN{OgxtEhOi5zMjFOwG0> MVuyOFA3PTV4OR?=
U373  MmqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEe1Xm4yOC1{MECg{txO NF[yVoQ6PiCq MlvQTWM2OD1zMD6xN{DDuSBzLkCyJO69VQ>? NFXMS|UzPDB4NUW2PS=>
HT-29  NUix[Ws6TnWwY4Tpc44hSXO|YYm= MX21NFAh|ryP M{\XdFI1NzR6IHi= NIDLbpNmdmijbnPld{B1cGVibHX2[Yx{KG:oIN8zMWgzSVkEoB?= M33r[|I1ODN6ME[4
PC-3  NHviT3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDJOWFoOC1{NTFOwG0> M3\IUlQ5KGh? NXHMPG5ZcW6qaXLpeJMh[2WubDDndo94fGhid3jpZ4gh[2GwIHLlJJBwfGWwdHnheIVlKGK7IHz5Z49x\W6n Mn;KNlM4PDZ7M{S=
PC-3  MVvBdI9xfG:|aYOgRZN{[Xl? M4myVlI2KM7:TR?= MUm0PEBp NF[1eVFqdmS3Y3XzJIFxd3C2b4Ppd{B4cGmlaDDjZY4h[mVicH;0[Y51cWG2ZXSgZpkhdHmlb4DlcoU> NVjJRZA{OjN5NE[5N|Q>
T98G NGDnWlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3UOVAuPDByIN88US=> NWfvO5N7OTR2IHi= MlrTbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M4n1SlI{PzF3NEm5
U87-MG M4mwOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{j4O|ExOCEEtV2= NGjIeGw4OiCq MXjpcohq[mm2czDj[YxtKGe{b4f0bEB4cGmlaDDjZY4h[mViZX7oZY5k\WRiYomgS3RD MmPYNlM3QTZ5OEi=
U251-MG MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4qwZ|ExOCEEtV2= NIHiUWk4OiCq M1j0UolvcGmkaYTzJINmdGxiZ4Lve5RpKHeqaXPoJINidiCkZTDlcohidmOnZDDifUBIXEJ? NU\hU3I2OjN4OU[3PFg>
LNT-229 MmfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXezMVExOCEQvF2= Mn;xNlQhcA>? MoP2bY5pcWKrdIOgZ4xwdm:pZX7pZ{B{fXK4aY\hcEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NXu4fVJEOjN4Nke2N|I>
T98G NWn0flh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWmxNE04ODBizszN MUmyOEBp Ml;FbY5pcWKrdIOgZ4xwdm:pZX7pZ{B{fXK4aY\hcEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NGjsNmszOzZ4N{[zNi=>
U87  MULGeY5kfGmxbjDBd5NigQ>? NGSxfWcyODBiwsXN M1fFZVMhcA>? NGPvboZmdGW4YYTld{B1cGVibHX2[Yx{KG:oIIDDbIsyKGGwZDDwR4hsOg>? MlzRNlM3Pjd2Nkm=
HCT116 MmS4SpVv[3Srb36gRZN{[Xl? NVLs[|NtOTByINM1US=> MnLQN{Bp M1L5dYlv\HWlZYOgeIhmKEOqa{GgVIhwe3Cqb4L5cIF1cW:w NHG1TI0zOzZ4N{S2PS=>
HCT3-6 NXjWbnR1TnWwY4Tpc44hSXO|YYm= NEDDSGkyODBiwsXN NXLXVpNOOyCq NITkcYdqdmS3Y3XzJJRp\SCFaHuxJHBpd3OyaH;yfYxifGmxbh?= NHv1XYszOzZ4N{S2PS=>
U-87  NXrkOINHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXuNE01OCEQvF2= NGjo[FIyOiCm Moi0bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MnTtNlM3PDV5Mkm=
U-87  Mk\ORZBweHSxc3nzJGF{e2G7 M{DSOlAuPDBizszN NVHLS3JSOy94IHS= M2DmN4lv\HWlZYOgZZBweHSxc3nzJIlvKGKxdHig[I9{\S1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? NVzudGJ7OjN4NEW3Nlk>
U-87  Ml7uSpVv[3Srb36gRZN{[Xl? Mm[zNE01OCEQvF2= Mm\uN{83KGR? NU\MdWNNcW6mdXPld{BifXSxcHjh[5khcW5iYn;0bEBld3OnLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ NX[4SIZVOjN4NEW3Nlk>
GB-SCC010 M1jCXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjHWpZ5PCCm M4jjTmlEPTB;MkK2JO69VQ>? M3XF[|I{PjF{N{W1
GB-SCC026 NYLlRm9nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3IOEBl NVvQdoc4UUN3ME21N{4yKM7:TR?= M37PRVI{PjF{N{W1
GB-SCC028 MkD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXm0JIQ> NW\ZRpBEUUN3ME2xOlch|ryP NVv0WGhUOjN4MUK3OVU>
U87 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HqNFQh\A>? MoH3TWM2OD12NT6yJO69VQ>? NYfvUJpnOjN4MUK3OVU>
U87 stem cell M{HyNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17uclQh\A>? MXrJR|UxRTZ4Lkeg{txO MUSyN|YyOjd3NR?=

... Click to View More Cell Line Experimental Data

In vivo After a daily i.p. dose of 40 mg/kg for 5 consecutive days (days 1-5 after tumor transplant), methazolastone increases life-span by 86% in L-1210 and 22% in L-1210/BCNU. In L-1210/BCNU no effect is seen after 100 μM or 200 μM treatment; only 400 μM methazolastone produced an accumulation of cells in premitotic phase but much less than in L-1210. In L-1210/BCNU the maximum accumulation of cells in SL-G2-M is, after 48 hours-72 hours, approximately 30% as compared to 23% in untreated cells. Cells accumulates in SL-G2-M occurred too when L- 1210 leukemia-bearing mice are treated i.v. with methazola stone (40 mg/kg). No such effect is seen on L-1210/BCNU cells from mice given the same drug dose. [1]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: L-1210 and L-1210/BCNU cells
  • Concentrations: 0 μM -100 μM
  • Incubation Time: l hours
  • Method:

    L-1210 and L-1210/BCNU cells are seeded at 0.2 × 104 cells/mL and incubated for 24 hours. The cultures are treated with Methazolastone for l hours at 37oC, then washed twice in PBS by centrifugation and resuspended in fresh medium. Controls and treated samples are diluted in fresh medium 1:4 at 48 hours and 1:2 at 96 hours. Using these dilutions cell concentrations throughout the experiments are between 3 × 105 and 8 × 105/mL. Control growth is logarithmic in this range.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: DBA/2 mice with L-1210 and L-1210/BCNU cells
  • Formulation: 95% ethanol
  • Dosages: 40 mg/kg
  • Administration: Administered via i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 38 mg/mL (195.72 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 194.15
Formula

C6H6N6O2

CAS No. 85622-93-1
Storage powder
in solvent
Synonyms CCRG81045, NSC 362856

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03528642 Not yet recruiting Anaplastic Astrocytoma IDH-Mutant|Diffuse Astrocytoma IDH-Mutant|IDH1 Gene Mutation|IDH2 Gene Mutation National Cancer Institute (NCI) February 8 2019 Phase 1
NCT03709680 Not yet recruiting Solid Tumors|Ewing Sarcoma|Rhabdoid Tumor|Rhabdomyosarcoma|Neuroblastoma|Medulloblastoma Pfizer February 5 2019 Phase 1
NCT03688178 Not yet recruiting Glioblastoma Gary Archer Ph.D.|Duke University January 2019 Phase 2
NCT03732482 Not yet recruiting Non Small Cell Lung Cancer Metastatic Taizhou Hospital January 1 2019 Phase 2|Phase 3
NCT03607643 Not yet recruiting Cancer of Pancreas|Cancer of Liver|Cancer of Rectum|Cancer of Colon|Cancer Gall Bladder|Myeloma Multiple|Glioblastoma Multiforme Leaf Vertical Inc. January 15 2019 Phase 1|Phase 2
NCT03705351 Not yet recruiting Glioblastoma|Cancer of Brain|Glioblastoma Multiforme|Brain Tumor Providence Health & Services|Providence Health & Services Brain & Spine Institute|University of California San Francisco|NovoCure Ltd. December 1 2018 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products0

Tags: buy Temozolomide | Temozolomide ic50 | Temozolomide price | Temozolomide cost | Temozolomide solubility dmso | Temozolomide purchase | Temozolomide manufacturer | Temozolomide research buy | Temozolomide order | Temozolomide mouse | Temozolomide chemical structure | Temozolomide mw | Temozolomide molecular weight | Temozolomide datasheet | Temozolomide supplier | Temozolomide in vitro | Temozolomide cell line | Temozolomide concentration | Temozolomide nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID